Granins as disease-biomarkers: Translational potential for psychiatric and neurological disorders

Neuroscience

Volumn 170, Issue 1, 2010, Pages 289-297

  Bartolomucci, A ^a,b   Pasinetti, G M ^b   Salton, S R J ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Chromogranin; Schizophrenia; Secretogranin; VGF

Indexed keywords

ACID PROTEIN; BIOLOGICAL MARKER; CELL PROTEIN; CHROMOGRANIN A; CHROMOGRANIN B; GRANIN; HISL 19 ANTIGEN; PROTEIN NESP55; PROTEIN PROSAAS; PROTEIN VGF; SECRETOGRANIN II; SECRETOGRANIN III; SECRETOGRANIN V; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE MARKER; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; MENTAL DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; RISK FACTOR; SCHIZOPHRENIA;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL MARKERS; CHROMOGRANINS; GENETIC MARKERS; HUMANS; MENTAL DISORDERS; MOLECULAR SEQUENCE DATA; NERVOUS SYSTEM DISEASES; PROTEIN BIOSYNTHESIS;

EID: 77955924374     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.06.057     Document Type: Review

References (79)

1. Banks P., Helle K.B. The release of protein from the stimulated adrenal medulla. Biochem J 1965, 97:40C-41C.
2. Bartolomucci A., La Corte G., Possenti R., Locatelli V., Rigamonti A.E., Torsello A., Bresciani E., Bulgarelli I., Rizzi R., Pavone F., D'Amato F.R., Severini C., Mignogna G., Giorgi A., Schininà M.E., Elia G., Brancia C., Ferri G.L., Conti R., Ciani B., Pascucci T., Dell'Omo G., Muller E.E., Levi A., Moles A. TLQP-21, a VGF-derived peptide, increases energy expenditure and prevents the early phase of diet-induced obesity. Proc Natl Acad Sci U S A 2006, 103:14584-14589.
3. Bartolomucci A., Possenti R., Levi A., Pavone F., Moles A. The role of the vgf gene and VGF-derived peptides in nutrition and metabolism. Genes Nutr 2007, 2:169-180.
4. Benedum U.M., Lamouroux A., Konecki D.S., Rosa P., Hille A., Baeuerle P.A., Frank R., Lottspeich F., Mallet J., Huttner W.B. The primary structure of human secretogranin. I (chromogranin B): comparison with chromogranin A reveals homologous terminal domains and a large intervening variable region. EMBO J 1987, 6:1203-1211.
5. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95. Biomarkers Definitions Working Group.
6. Blennow K., Davidsson P., Wallin A., Ekman R. Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer's disease?. Dementia 1995, 6:306-311.
7. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
8. Carrette O., Demalte I., Scherl A., Yalkinoglu O., Corthals G., Burkhard P., Hochstrasser D.F., Sanchez J.C. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3:1486-1494.
9. Conlon JM (in press) Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors. Regul Pept; doi:10.1016/j.regpep.2009.11.013.
10. Courel M., Rodemer C., Nguyen S.T., Pance A., Jackson A.P., O'Connor D.T., Taupenot L. Secretory granule biogenesis in sympathoadrenal cells: identification of a granulogenic determinant in the secretory prohormone chromogranin A. J Biol Chem 2006, 281:38038-38051.
11. Davidsson P., Sjögren M., Andreasen N., Lindbjer M., Nilsson C.L., Westman-Brinkmalm A., Blennow K. Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 2002, 109:128-133.
12. Eiden L. Is chromogranin A a prohormone?. Nature 1987, 325:301.
13. Eiden L.E., Huttner W.B., Mallet J., O'Connor D.T., Winkler H., Zanini A. A nomenclature proposal for the chromogranin/secretogranin proteins. Neuroscience 1987, 21:1019-1021.
14. Ferri G.L., Possenti R. vgf A neurotrophin-inducible gene expressed in neuroendocrine tissues. Trends Endocrinol Metab 1996, 7:233-239.
15. Fischer-Colbrie R., Laslop A., Kirchmair R. Secretogranin. II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 1995, 46:49-70.
16. Greenway M.J., Andersen P.M., Russ C., Ennis S., Cashman S., Donaghy C., Patterson V., Swingler R., Kieran D., Prehn J., Morrison K.E., Green A., Acharya K.R., Brown R.H., Hardiman O. ANG mutations segregate with familial and "sporadic" amyotrophic lateral sclerosis. Nat Genet 2006, 38:411-413.
17. Gros-Louis F., Andersen P.M., Dupre N., Urushitani M., Dion P., Souchon F., D'Amour M., Camu W., Meininger V., Bouchard J.P., Rouleau G.A., Julien J.P. Chromogranin B P413L variant as risk factor and modifier of disease onset for amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2009, 106:21777-21782.
18. Harsha H.C., Kandasamy K., Ranganathan P., Rani S., Ramabadran S., Gollapudi S., Balakrishnan L., Dwivedi S.B., Telikicherla D., Selvan L.D., Goel R., Mathivanan S., Marimuthu A., Kashyap M., Vizza R.F., Mayer R.J., Decaprio J.A., Srivastava S., Hanash S.M., Hruban R.H., Pandey A. A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009, 6:e1000046.
19. Helle K.B. The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev 2004, 79:769-794.
20. Helle K.B. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res 2010, 85:9-16.
21. Huang J.T., Leweke F.M., Oxley D., Wang L., Harris N., Koethe D., Gerth C.W., Nolden B.M., Gross S., Schreiber D., Reed B., Bahn S. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006, 3:e428.
22. Huang J.T., Leweke F.M., Tsang T.M., Koethe D., Kranaster L., Gerth C.W., Gross S., Schreiber D., Ruhrmann S., Schultze-Lutter F., Klosterkötter J., Holmes E., Bahn S. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2007, 2:e756.
23. Hunsberger J.G., Newton S.S., Bennett A.H., Duman C.H., Russell D.S., Salton S.R., Duman R.S. Antidepressant actions of the exercise-regulated gene VGF. Nat Med 2007, 13:1476-1482.
24. Huttner W.B., Gerdes H.H., Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci 1991, 16:27-30.
25. Iijima Y., Inada T., Ohtsuki T., Senoo H., Nakatani M., Arinami T. Association between chromogranin b gene polymorphisms and schizophrenia in the Japanese population. Biol Psychiatry 2004, 56:10-17.
26. Jethwa P.H., Warner A., Nilaweera K.N., Brameld J.M., Keyte J.W., Carter W.G., Bolton N., Bruggraber M., Morgan P.J., Barrett P., Ebling F.J. VGF-derived peptide, TLQP-21, regulates food intake and body weight in Siberian hamsters. Endocrinology 2007, 148:4044-4055.
27. Kamboh M.I. Molecular genetics of late-onset Alzheimer's disease. Ann Hum Genet 2004, 68:381-404.
28. Kikuchi K., Arawaka S., Koyama S., Kimura H., Ren C.H., Wada M., Kawanami T., Kurita K., Daimon M., Kawakatsu S., Kadoya T., Goto K., Kato T. An N-terminal fragment of ProSAAS (a granin-like neuroendocrine peptide precursor) is associated with tau inclusions in Pick's disease. Biochem Biophys Res Commun 2003, 308:646-654.
29. Kirchmair R., Hogue-Angeletti R., Gutierrez J., Fischer-Colbrie R., Winkler H. Secretoneurin-a neuropeptide generated in brain, adrenal medulla and other endocrine tissues by proteolytic processing of secretogranin. II (chromogranin C). Neuroscience 1993, 53:359-365.
30. Kitao Y., Inada T., Arinami T., Hirotsu C., Aoki S., Iijima Y., Yamauchi T., Yagi G. A contribution to genome-wide association studies: search for susceptibility loci for schizophrenia using DNA microsatellite markers on chromosomes 19, 20, 21 and 22. Psychiatr Genet 2000, 10:139-143.
31. Koshimizu H., Kim T., Cawley N.X., Loh Y.P. Chromogranin A: a new proposal for trafficking, processing and induction of granule biogenesis. Regul Pept 2010, 160:153-159.
32. Landén M., Davidsson P., Gottfries C.G., Grenfeldt B., Stridsberg M., Blennow K. Reduction of the small synaptic vesicle protein synaptophysin but not the large dense core chromogranins in the left thalamus of subjects with schizophrenia. Biol Psychiatry 1999, 46:1698-1702.
33. Landén M., Grenfeldt B., Davidsson P., Stridsberg M., Regland B., Gottfries C.G., Blennow K. Reduction of chromogranin A and B but not C in the cerebrospinal fluid in subjects with schizophrenia. Eur Neuropsychopharmacol 1999, 9:311-315.
34. Lechner T., Adlassnig C., Humpel C., Kaufmann W.A., Maier H., Reinstadler-Kramer K., Hinterhölzl J., Mahata S.K., Jellinger K.A., Marksteiner J. Chromogranin peptides in Alzheimer's disease. Exp Gerontol 2004, 39:101-113.
35. Lee V.M., Goedert M., Trojanowski J.Q. Neurodegenerative tauopathies. Annu Rev Neurosci 2001, 24:1121-1159.
36. Levi A., Eldridge J.D., Paterson B.M. Molecular cloning of a gene sequence regulated by nerve growth factor. Science 1985, 229:393-395.
37. Levi A., Ferri G.L., Watson E., Possenti R., Salton S.R. Processing, distribution, and function of VGF, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol 2004, 24:517-533.
38. Mahata S.K., O'Connor D.T., Mahata M., Yoo S.H., Taupenot L., Wu H., Gill B.M., Parmer R.J. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997, 100:1623-1633.
39. Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., Komure O., Matsuura S., Kobatake K., Morimoto N., Abe K., Suzuki N., Aoki M., Kawata A., Hirai T., Kato T., Ogasawara K., Hirano A., Takumi T., Kusaka H., Hagiwara K., Kaji R., Kawakami H. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
40. Mattsson N., Rüetschi U., Podust V.N., Stridsberg M., Li S., Andersen O., Haghighi S., Blennow K., Zetterberg H. Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 2007, 103:1932-1939.
41. Miller C., Kirchmair R., Troger J., Saria A., Fleischhacker W.W., Fischer-Colbrie R., Benzer A., Winkler H. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol Psychiatry 1996, 39:911-918.
42. Moss A., Ingram R., Koch S., Theodorou A., Low L., Baccei M., Hathway G.J., Costigan M., Salton S.R., Fitzgerald M. Origins, actions and dynamic expression patterns of the neuropeptide VGF in rat peripheral and central sensory neurones following peripheral nerve injury. Mol Pain 2008, 4:62.
43. Munoz D.G. Chromogranin A-like immunoreactive neurites are major constituents of senile plaques. Lab Invest 1991, 64:826-832.
44. Nowakowski C., Kaufmann W.A., Adlassnig C., Maier H., Salimi K., Jellinger K.A., Marksteiner J. Reduction of chromogranin B-like immunoreactivity in distinct subregions of the hippocampus from individuals with schizophrenia. Schizophr Res 2002, 58:43-53.
45. Obayashi K., Sato K., Shimazaki R., Ishikawa T., Goto K., Ueyama H., Mori T., Ando Y., Kumamoto T. Salivary chromogranin A: useful and quantitative biochemical marker of affective state in patients with amyotrophic lateral sclerosis. Intern Med 2008, 47:1875-1879.
46. O'Connor D.T., Kailasam M.T., Thal L.J. Cerebrospinal fluid chromogranin A is unchanged in Alzheimer dementia. Neurobiol Aging 1993, 14:267-269.
47. Pasinetti G.M., Ungar L.H., Lange D.J., Yemul S., Deng H., Yuan X., Brown R.H., Cudkowicz M.E., Newhall K., Peskind E., Marcus S., Ho L. Identification of potential CSF biomarkers in ALS. Neurology 2006, 66:1218-1222.
48. Riedl M.S., Braun P.D., Kitto K.F., Roiko S.A., Anderson L.B., Honda C.N., Fairbanks C.A., Vulchanova L. Proteomic analysis uncovers novel actions of the neurosecretory protein VGF in nociceptive processing. J Neurosci 2009, 29:13377-13388.
49. Rizzi R., Bartolomucci A., Moles A., D'Amato F., Sacerdote P., Levi A., La Corte G., Ciotti M.T., Possenti R., Pavone F. The VGF-derived peptide TLQP-21: a new modulatory peptide for inflammatory pain. Neurosci Lett 2008, 441:129-133.
50. Rosa P., Zanini A. Characterization of adenohypophysial polypeptides by two-dimensional gel electrophoresis: II. Sulfated and glycosylated polypeptides. Mol Cell Endocrinol 1981, 24:181-193.
51. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
52. Rüetschi U., Zetterberg H., Podust V.N., Gottfries J., Li S., Hviid Simonsen A., McGuire J., Karlsson M., Rymo L., Davies H., Minthon L., Blennow K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp Neurol 2005, 196:273-281.
53. Sahu B.S., Sonawane P.J., Mahapatra N.R. Chromogranin A: a novel susceptibility gene for essential hypertension. Cell Mol Life Sci 2010, 67:861-874.
54. Salton S.R., Ferri G.L., Hahm S., Snyder S.E., Wilson A.J., Possenti R., Levi A. VGF: a novel role for this neuronal and neuroendocrine polypeptide in the regulation of energy balance. Front Neuroendocrinol 2000, 21:199-219.
55. Salton S.R., Fischberg D.J., Dong K.W. Structure of the gene encoding VGF, a nervous system-specific mRNA that is rapidly and selectively induced by nerve growth factor in PC12 cells. Mol Cell Biol 1991, 11:2335-2349.
56. Schiffer D., Cordera S., Giordana M.T., Attanasio A., Pezzulo T. Synaptic vesicle proteins, synaptophysin and chromogranin A in amyotrophic lateral sclerosis. J Neurol Sci 1995, 129:68-74.
57. Schrott-Fischer A., Bitsche M., Humpel C., Walcher C., Maier H., Jellinger K., Rabl W., Glueckert R., Marksteiner J. Chromogranin peptides in amyotrophic lateral sclerosis. Regul Pept 2009, 152:13-21.
58. Severini C., La Corte G., Improta G., Broccardo M., Agostini S., Petrella C., Sibilia V., Pagani F., Guidobono F., Bulgarelli I., Ferri G.L., Brancia C., Rinaldi A.M., Levi A., Possenti R. In vitro and in vivo pharmacological role of TLQP-21, a VGF-derived peptide, in the regulation of rat gastric motor functions. Br J Pharmacol 2009, 157:984-993.
59. Simonsen A.H., McGuire J., Podust V.N., Hagnelius N.O., Nilsson T.K., Kapaki E., Vassilopoulos D., Waldemar G. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 2007, 24:434-440.
60. Snyder S.E., Salton S.R. Expression of VGF mRNA in the adult rat central nervous system. J Comp Neurol 1998, 394:91-105.
61. Sonnen J.A., Montine K.S., Quinn J.F., Kaye J.A., Breitner J.C., Montine T.J. Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurol 2008, 7:704-714.
62. Sreedharan J., Blair I.P., Tripathi V.B., Hu X., Vance C., Rogelj B., Ackerley S., Durnall J.C., Williams K.L., Buratti E., Baralle F., de Belleroche J., Mitchell J.D., Leigh P.N., Al-Chalabi A., Miller C.C., Nicholson G., Shaw C.E. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
63. Stoop M.P., Dekker L.J., Titulaer M.K., Burgers P.C., Sillevis Smitt P.A., Luider T.M., Hintzen R.Q. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8:1576-1585.
64. Stoop M.P., Dekker L.J., Titulaer M.K., Lamers R.J., Burgers P.C., Sillevis Smitt P.A., van Gool A.J., Luider T.M., Hintzen R.Q. Quantitative matrix-assisted laser desorption ionization-fourier transform ion cyclotron resonance (MALDI-FT-ICR) peptide profiling and identification of multiple-sclerosis-related proteins. J Proteome Res 2009, 8:1404-1414.
65. Takahashi N., Ishihara R., Saito S., Maemo N., Aoyama N., Ji X., Miura H., Ikeda M., Iwata N., Suzuki T., Kitajima T., Yamanouchi Y., Kinoshita Y., Ozaki N., Inada T. Association between chromogranin A gene polymorphism and schizophrenia in the Japanese population. Schizophr Res 2006, 83:179-183.
66. Taupenot L., Harper K.L., O'Connor D.T. The chromogranin-secretogranin family. N Engl J Med 2003, 348:1134-1149.
67. Thakker-Varia S., Krol J.J., Nettleton J., Bilimoria P.M., Bangasser D.A., Shors T.J., Black I.B., Alder J. The neuropeptide VGF produces antidepressant-like behavioural effects and enhances proliferation in the hippocampus. J Neurosci 2007, 27:12156-12167.
68. Toshinai K., Nakazato M. Neuroendocrine regulatory peptide-1 and -2: novel bioactive peptides processed from VGF. Cell Mol Life Sci 2009, 66:1939-1945.
69. Toshinai K, Yamaguchi H, Kageyama H, Matsuo T, Koshinaka K, Sasaki K, Shioda S, Minamino N, Nakazato M (in press) Neuroendocrine regulatory peptide-2 regulates feeding behavior via the orexin system in the hypothalamus. Am J Physiol Endocrinol Metab; doi:10.1152/ajpendo.00768.2009.
70. Trani E., Ciotti T., Rinaldi A.M., Canu N., Ferri G.L., Levi A., Possenti R. Tissue-specific processing of the neuroendocrine protein VGF. J Neurochem 1995, 65:2441-2449.
71. Urushitani M., Sik A., Sakurai T., Nukina N., Takahashi R., Julien J.P. Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat Neurosci 2006, 9:108-118.
72. van Kammen D.P., Peters J., Yao J., Neylan T., Beuger M., Pontius E., O'Connor D.T. CSF chromogranin A-like immunoreactivity in schizophrenia. Assessment of clinical and biochemical relationships. Schizophr Res 1991, 6:31-39.
73. Wada M., Ren C.H., Koyama S., Arawaka S., Kawakatsu S., Kimura H., Nagasawa H., Kawanami T., Kurita K., Daimon M., Hirano A., Kato T. A human granin-like neuroendocrine peptide precursor (proSAAS) immunoreactivity in tau inclusions of Alzheimer's disease and parkinsonism-dementia complex on Guam. Neurosci Lett 2004, 356:49-52.
74. Weiler R., Lassmann H., Fischer P., Jellinger K., Winkler H. A high ratio of chromogranin A to synaptin/synaptophysin is a common feature of brains in Alzheimer and Pick disease. FEBS Lett 1990, 263:337-339.
75. Winkler H., Fischer-Colbrie R. The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 1992, 49:497-528.
76. Yajima A., Ikeda M., Miyazaki K., Maeshima T., Narita N., Narita M. Manserin, a novel peptide from secretogranin II in the neuroendocrine system. Neuroreport 2004, 15:1755-1759.
77. Yamaguchi H., Sasaki K., Satomi Y., Shimbara T., Kageyama H., Mondal M.S., Toshinai K., Date Y., González L.J., Shioda S., Takao T., Nakazato M., Minamino N. Peptidomic identification and biological validation of neuroendocrine regulatory peptide-1 and -2. J Biol Chem 2007, 282:26354-26360.
78. Yasuhara O., Kawamata T., Aimi Y., McGeer E.G., McGeer P.L. Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases. Neurosci Lett 1994, 170:13-16.
79. Zhao Z., Lange D.J., Ho L., Bonini S., Shao B., Salton S.R., Thomas S., Pasinetti G.M. Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis. Int J Med Sci 2008, 5:92-99.